The European Medicines Agency could decide within weeks whether the COVID-19 vaccines being developed by BioNTech/Pfizer and Moderna respectively should be granted pan-EU marketing approval.
Applications for the conditional marketing authorization (CMA) of BioNTech/Pfizer’s BNT162b2 and Moderna’s mRNA-1273 have now been received, the EMA said...







